Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9Q5UP
|
|||
| Drug Name |
TBA-354
|
|||
| Synonyms |
1257426-19-9; TBA354; (s)-2-nitro-6-((6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methoxy)-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine; UNII-911T37M2WY; TBA 354; 911T37M2WY; (6S)-2-Nitro-6-({6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl}methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]-3-pyridyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; SCHEMBL508426; CHEMBL1630563; EX-A526; MFCD28009369; ZINC66252280; AKOS025404945; CS-3576; SB17064; NCGC00390647-01; HY-12485; B5935; Q27896161; ((6S)-6-((6-(4-(Trifluoromethoxy)phenyl)-3-pyridyl)methoxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazin-2-yl)azinic acid; (6S)-6,7-Dihydro-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]-3-pyridinyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; (sn31354((S)-2-Nitro-6-((6-(4-trifluoromethoxy)phenyl)pyridine-3-yl)methoxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine)); 5H-Imidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]-3-pyridinyl]methoxy]-, (6S)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Tuberculosis [ICD-11: 1B10-1B14] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H15F3N4O5
|
|||
| Canonical SMILES |
C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CN=C(C=C3)C4=CC=C(C=C4)OC(F)(F)F
|
|||
| InChI |
1S/C19H15F3N4O5/c20-19(21,22)31-14-4-2-13(3-5-14)16-6-1-12(7-23-16)10-29-15-8-25-9-17(26(27)28)24-18(25)30-11-15/h1-7,9,15H,8,10-11H2/t15-/m0/s1
|
|||
| InChIKey |
ZXSGSFMORAILEY-HNNXBMFYSA-N
|
|||
| CAS Number |
CAS 1257426-19-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02288481) A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.